Chimeric antigen receptor (CAR) T cells are changing the therapeutic landscape for
hematological malignancies. To date, all six CAR T cell products approved by the US Food …

Overview IL-7 is a member of the family of cytokines with four anti-parallel α helixes that bind
Type I cytokine receptors. It is produced by stromal cells and is required for development …

Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly
diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic …

Background Chimeric antigen receptor (CAR) T-cell therapy is a promising option for
patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the …

We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells
targeting CD19) in adult and pediatric patients with relapsed/refractory CD19+ …

Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its
immune-oncology pipeline over the last years. This is in great part due to the recent …

The antitumor efficacy of genetically engineered 'living drugs', including chimeric antigen
receptor and T-cell receptor T cells, is influenced by their activation, proliferation, inhibition …

Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment
of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus …

Abstract In February 2021, the 'Advanced Therapy Medicinal Product'(ATMP) ARI-0001
(CART19-BE-01), developed at Hospital Clínic de Barcelona (Spain), received authorization …

Harnessing the human immune system as a foundation for therapeutic technologies capable
of recognizing and killing tumor cells has been the central objective of anti-cancer …